RedHill Biopharma (RDHL) Study Shows opaganib's Strong Inhibition of COVID-19 Delta Variant

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to RedHill Biopharma (RDHL) Study Shows opaganib's Strong Inhibition of COVID-19 Delta Variant

RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant

August 26, 2021 6:00 AM EDT

TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing strong inhibition by opaganib (ABC294640)[1] of Delta variant replication while maintaining cell viability at relevant... More